Tetranectin Knockout Mice Develop Features of Parkinson Disease

Background/Aims: Aggregation of insoluble α-synuclein to form Lewy bodies (LBs) may contribute to the selective loss of midbrain dopaminergic neurons in Parkinson disease (PD). Lack of robust animal models has impeded elucidation of the molecular mechanisms of LB formation and other critical aspects...

Full description

Saved in:
Bibliographic Details
Published inCellular physiology and biochemistry Vol. 34; no. 2; pp. 277 - 287
Main Authors Wang, Er-song, Zhang, Xiao-ping, Yao, Hui-bin, Wang, Gan, Chen, Shi-wen, Gao, Wen-wei, Yao, Hai-jun, Sun, Yi-rui, Xi, Cai-hua, Ji, Yao-dong
Format Journal Article
LanguageEnglish
Published Basel, Switzerland Cell Physiol Biochem Press GmbH & Co KG 01.01.2014
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background/Aims: Aggregation of insoluble α-synuclein to form Lewy bodies (LBs) may contribute to the selective loss of midbrain dopaminergic neurons in Parkinson disease (PD). Lack of robust animal models has impeded elucidation of the molecular mechanisms of LB formation and other critical aspects of PD pathogenesis. Methods: We established a mouse model with targeted deletion of the plasminogen-binding protein tetranectin (TN) gene (TN -/- ) and measured the behavioral and histopathological features of PD. Results: Aged (15-to 20-month-old) TN -/- mice displayed motor deficits resembling PD symptoms, including limb rigidity and both slower ambulation (bradykinesia) and reduced rearing activity in the open field. In addition, these mice exhibited more numerous α-synuclein-positive LB-like inclusions within the substantia nigra pars compacta (SNc) and reduced numbers of SNc dopaminergic neurons than age-matched wild type (WT) mice. These pathological changes were also accompanied by loss of dopamine terminals in the dorsal striatum. Conclusion: The TN -/- mouse exhibits several key features of PD and so may be a valuable model for studying LB formation and testing candidate neuroprotective therapies for PD and other synucleinopathies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1015-8987
1421-9778
DOI:10.1159/000362998